SEC Form 4 · accession 0001394548-16-000004
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J Knapp
Officer — General Counsel
Period of report
Oct 25, 2016
Accepted (ET)
Dec 20, 2016 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2,F3 | $0.29 | Oct 25, 2016 | A | 102,000 | A | — | Oct 25, 2026 | Common Stock | 102,000 | 102,000 | D |
Explanation of responses
- F1Granted pursuant to the Issuer's 2016 Incentive Plan.
- F2The Reporting Person obtained the securities pursuant to an Employment Agreement Amendment dated October 1, 2016. The securities were convertible into common stock at the rate of 1 share of common stock for each 1 stock option share, or an aggregate of 102,000 shares of common stock (pre-reverse stock split). The securities were converted into 5,100 stock options at a price of $5.744 per share (post-reverse split) as of November 14, 2016.
- F3This stock option vests in equal monthly installments beginning November 25, 2016 and ending March 31, 2017.